Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity|
|Abstract:||Disclosed herein is cis-oxalato (trans-1-1,2-cyclohexanediamine) Pt(II) optically high purity. Because of its complete optical purity, the compound is effective as raw material of such a medicine as a carcinostatic agent. The complete optical purity of the above compound may be proved by comparing the respective melting points of the cis-oxalato (trans-1-1,2-cyclohexanediamine).|
|Inventor(s):||Nakanishi; Chihiro (Kanagawa, JP), Ohnishi; Yuko (Kanagawa, JP), Ohnishi; Junji (Kanagawa, JP), Taniuchi; Junichi (Kanagawa, JP), Okamoto; Koji (Kanagawa, JP), Tozawa; Takeshi (Kanagawa, JP)|
|Assignee:||Tanaka Kikinzoku Kogyo K.K. (JP)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||5-019508||Jan 12, 1993|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Germany||69322992||<disabled in preview>|
|European Patent Office||0567438||<disabled in preview>|
|Spain||2125320||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.